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Abstract 
Background  
Oxygen is widely recommended in international guidelines for treatment of acute 
myocardial infarction (AMI), but there is uncertainty about its safety and benefits.  
Objectives 
A systematic review and meta-analysis were performed to determine whether inhaled 
oxygen in AMI improves pain or the risk of death. 
Methods 
Cochrane CENTRAL Register of Controlled Trials, MEDLINE, MEDLINE In-Process, 
EMBASE, CINAHL, LILACS and PASCAL were searched from start date through 
February 2010. Other sources included British Library ZETOC, Web of Science, ISI 
Proceedings, conferences of relevant societies, contact with experts. Randomised 
controlled trials of inhaled oxygen (at normal pressure) versus air in patients with 
suspected or proven AMI of less than 24 hours onset were included. Two authors 
independently reviewed studies to see if they met inclusion criteria and undertook data 
abstraction. Quality of studies and risk of bias was assessed according to Cochrane 
Collaboration guidance. The main outcomes were death, pain, and complications. The 
measure of effect used was the relative risk (RR). 
Results 
Three trials, involving 387 patients were included. The pooled RR of death on oxygen 
compared to air was 2.88 (95%CI 0.88 to 9.39) on an ITT analysis and 3.03 (95%CI 0.93 
to 9.83) in confirmed AMI.  While suggestive of harm, this could be a chance occurrence.  
Pain was measured by analgesic use. The pooled RR for the use of analgesics was 0.97 
(95%CI 0.78 to 1.20).  
Conclusion 
The evidence in this area is sparse, of poor quality and pre-dates advances in reperfusion 
techniques and trial methods. What evidence there is, is suggestive of harm but lacks 
power and excess deaths in the O2 group could be due to chance.  More research is 
urgently needed to clarify the role of oxygen in AMI. 
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Systematic review registration number 
Original protocol registered with the Cochrane Collaboration. 
RevMan ID 848507032313175590, DOI: 10.1002/14651858.CD007160  
 
The Corresponding Author has the right to grant on behalf of all authors and does grant 
on behalf of all authors, an exclusive licence (or non exclusive for government employees) 
on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to 
be published in JNL and any other BMJPGL products and sublicences such use and 
exploit all subsidiary rights, as set out in our licence 
(http://group.bmj.com/products/journals/instructions-for-authors/licence-forms). 
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Abbreviations 
O2   Oxygen 
AMI  Acute myocardial infarction 
ECG Electrocardiograph 
PCI Primary coronary intervention 
SaO2 Oxygen saturation 
STEMI ST segment elevation myocardial infarction 
RCT Randomised controlled trial 
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Introduction 
The cornerstone of contemporary management of AMI presenting with ST segment 
elevation is reperfusion therapy. Other recommended treatments include: aspirin; nitrates; 
morphine; and O2. While O2 administration is mentioned in most AMI guidelines, 
recommendations are inconsistent.1-9   
The rationale for providing O2 in AMI is to improve oxygenation of ischaemic myocardial 
tissue. This has face validity but is there supporting evidence?  A systematic review, 
including non-randomised studies, did not confirm that O2 reduces acute myocardial 
ischaemia (some evidence suggested it may actually increase ischaemia).10  A systematic 
review of the effect on infarct size concluded ‘There is little evidence by which to 
determine the efficacy and safety of high flow oxygen therapy in MI. The evidence that 
does exist suggests that the routine use of high flow oxygen in uncomplicated MI may 
result in a greater infarct size and possibly increase the risk of mortality’.11  
A recent narrative review 12 also suggested that oxygen may do more harm than good.  
The British Heart Foundation’s response to this was: ‘The current practice of giving high-
flow O2 is an important part of heart attack treatment. Best practice methods have been 
developed and refined over the years to ensure the best possible outcome for patients. 
There is not enough evidence to change the current use of O2 therapy in heart attacks.’ 13  
This view is consistent with that held by many clinicians who treat AMI.14, 15 
Given the uncertainty surrounding this widely used treatment, we undertook a systematic 
review to look at the effect on patient-centred clinical outcomes of giving O2 to people with 
suspected AMI. 
Methods 
Protocol and registration 
The protocol was registered on the Cochrane Library.16  
Eligibility criteria 
Study design: randomised controlled trials, with any length of follow up. 
Participants: patients treated in a pre-hospital or a hospital setting for suspected 
or proven uncomplicated AMI of less than 24 hours onset, regardless of co-
therapies (e.g. reperfusion), provided these were the same in both arms. 
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Intervention: inhaled O2, at normal pressure, for one hour or more, at any stage 
within 24 hours after the onset of AMI.  Hyperbaric and aqueous O2 therapy trials 
were excluded. 
Comparator: air 
Publication status: any 
Language: any 
Years: any 
 
Information sources  
We searched the Cochrane CENTRAL Register of Controlled Trials, MEDLINE, MEDLINE 
In-Process, EMBASE, CINAHL, LILACS and PASCAL, UK National Research Register 
(NRR) to 2007, the NRR Archive and NIHR CRN portfolio, Current Controlled Trials 
metaRegister and ClinicalTrials.gov. Other sources included British Library ZETOC, Web 
of Science, ISI Proceedings, annual meetings and conferences of the American College of 
Cardiology, American Heart Association, British Cardiovascular Society and European 
Society of Cardiology.  
Search strategy 
Databases were searched from their start date through February 2010.  The strategy 
specified in the protocol was amended to increase sensitivity by truncating the term 
“oxygen”. (See appendix 1 for full strategy).    
Study selection  
Two authors independently reviewed titles and abstracts of identified studies to see if they 
met the inclusion criteria. If this could not be decided from the title or abstract study 
reports were obtained in full. There were no discrepancies. 
Data collection process 
Data were abstracted using a piloted data extraction form independently by two reviewers 
and entered by one reviewer and checked by two others.  Differences were resolved by 
discussion.  
Data items 
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The primary outcome was pre-specified as mortality; secondary outcomes were pain (or 
opiate use as a proxy), quality of life and any other reported patient-centred outcomes.  
Surrogate outcomes such as arrhythmias, infarct size and SaO2 were not collected. 
Risk of bias in individual studies 
We used the Cochrane Collaboration two-part tool.17  We considered six domains: 
sequence generation; allocation concealment; blinding (participants, personnel and 
outcome assessors); incomplete outcome data; selective outcome reporting; and other 
potential threats to validity.  For each trial the design characteristics relating to each 
domain we judged the risk of bias associated with the main outcome using a nominal 
scale: ‘Yes‘ (low risk of bias) ‘No’ (high risk of bias) or ‘Unclear’ (uncertain risk of bias), for 
all the relevant outcomes in the relevant domains. 
Risk of bias across studies 
We assessed overall risk of bias for every outcome by each domain using the following 
scale: low (‘Yes’  in all domains), unclear (‘Unclear’ for one or more domains) and high 
(‘No’ for one or more domains).  
Where meta-analysis was undertaken, we summarised risk of bias across studies.  
Disagreements were resolved by consensus.  
Summary measures 
We calculated risk difference and relative risk (RR) of death.  As the trials were old, we 
anticipated that control event rates would be higher than those expected today and 
therefore pre-specified that we would preferentially report the RR.  Intention-to-treat  (ITT) 
analysis was performed whenever possible. 
Synthesis of results 
We used RevMan 5.0. Meta-analyses were performed when clinically sensible and data 
available using a fixed effects model.  ITT analysis was the primary analysis but we also 
looked at results in patients with proven AMI.  We assessed heterogeneity by visual 
inspection and the I2 statistic (I2 < 60% was considered moderate). 
Additional analyses 
We undertook a best-case worst-case sensitivity analysis for missing data on death for 
confirmed AMI and ITT populations. 
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Results  
Study selection 
We identified 2529 articles.  Removal of duplicates left 2228. Based on title and 
abstract, 2094 were excluded, 134 full papers retrieved.  A further 115 were excluded, 
leaving four papers reporting three trials17-20 that met the inclusion criteria.  (Figure 1 
gives reasons for exclusions.)  
Study characteristics 
All three studies were parallel design RCTs. One 18 was double-blind, the others were 
open label. Table 1 shows the main characteristics of included studies. 
Rawles18 1976 
This study was the largest (N=200) and had the best methodology.  It was performed in 
the pre-reperfusion era.  Patients with suspected AMI were randomised and followed to 
discharge. 
Wilson19 1997 
This was a small RCT of 50 people with confirmed uncomplicated AMI, followed to 
discharge.  Its primary purpose was to look at the effect of O2 on hypoxaemia and did not 
record most of the outcomes of interest to this review. It was reported along with a postal 
survey on the use of O2 and pulse oximetry in 252 cardiac care units in the UK.   
Ukholkina20,21 2005 
This study was published in English 20 and Russian.21  It is the only trial performed in the 
PCI era and included 137 patients with confirmed uncomplicated AMI.  Its primary 
purpose was to look at infarct size.  Patients were followed for 10 days. 
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Table 1 - Characteristics of included studies 
 
 
Trial & 
year 
Study 
design and 
sample size 
Clinical 
setting  
Participants  Exclusions Intervention Comparator Outcomes Length of 
follow-
up 
Clinical 
Context and 
parallel  care 
Rawles 
1976 
18 
Double-
blind, 
randomised 
controlled 
trial 
N=200 
Single 
site 
coronary 
care unit 
in the 
UK 
 
Suspected 
acute 
myocardial 
infarction (MI) 
presenting 
within 24 
hours of onset 
of pain 
Patients 
with heart 
failure, 
Bronchitis, 
emphysema, 
or other 
respiratory 
problems 
Inhaled 
oxygen at 
normal 
pressure 
given at 
6L/min by 
MC mask for  
24 hours 
N: 105 
Air at 
normal 
pressure 
given at 
6L/min by 
MC mask.  
 
N: 95 
Death, 
arrhythmias, 
use of 
analgesics, 
length of 
stay (LOS). 
Discharge Pre-
thrombolysis 
period 
Wilson 
1997 
19 
 
 
Open label 
randomised 
controlled 
trial 
N= 50 
 
Single 
site 
coronary 
care unit 
in the 
UK 
 
Confirmed 
uncomplicated 
acute MI   
 
Patients with 
heart failure, 
cyanosis 
central or 
pulmonary 
disease 
requiring O2 
Oxygen for 
24 hours 
administered 
via face 
mask at 
4L/min.  
N:25 
 
Air 
breathed 
normally 
 
 
N:25 
Hypoxaemia, 
Arrhythmias, 
analgesics, 
and Cardiac 
enzymes 
 
Discharge Thrombolysis 
period 
Ukholkina 
2005 
20,21 
 
Open label 
randomised 
controlled 
trial 
N=137 
Single 
site 
coronary 
care unit 
in Russia 
 
Confirmed 
uncomplicated 
acute MI  
 
Patients with 
complicated 
MI, 
congestive 
heart failure, 
pulmonary 
disease, or 
anaemia. 
Oxygen for 3 
hours 
administered 
via nasal 
cannulae 3-6 
L/min (Fio2 
30-40%) 
N:58 
Air 
breathed 
normally 
 
 
N: 79 
Death, 
recurrent 
AMI, post-
infarction 
angina, 
heart failure, 
area of 
tissue 
damage 
measured by 
ECG 
mapping, 
cardiac 
enzymes. 
10 days 
 
PCI era 
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Risk of bias within studies 
Risk of bias for each study is summarised in figure 2. Reasons underlying these 
classifications are given below.  
Rawles 18 1976 
There is no description of how the randomisation sequence was generated. Allocation 
was concealed using numbered sealed envelopes. The groups had similar baseline 
characteristics. Blinding of patients and staff was by shrouding gas cylinders. There is no 
information on how effective this was.  If patients required O2 due to severe hypoxaemia 
or cardiac arrest, blinding was not broken - the tube was attached to a wall supply of O2. 
While the primary outcome of this review, death, is not subject to observer bias, the 
possibility of performance bias due to unblinding cannot be excluded.  The patients 
withdrawn from the study are not reported, so we cannot estimate the possible impact of 
performance bias on outcomes.  Nursing staff were not aware that routine recording of 
opiate administration would be used as a proxy measurement of pain.  
There was no loss to follow-up, but randomisation was undertaken before the diagnosis 
was confirmed.  Of the 105 people randomised to O2 and the 95 to air, AMI was not 
confirmed in 25 and 18 patients, respectively. Characteristics of those in whom AMI was 
not confirmed were similar in both groups and there were no deaths in these individuals.  
No selective reporting bias was identified.  
Wilson 19 1997 
There is no description of how the randomisation was done. Allocation was concealed 
using sealed envelopes. The baseline characteristics showed the groups to be similar in 
mean age and smoking habits. The study was not blind. In total eight patients were 
excluded from the analysis: 1 death, 1 stroke, 4 withdrew consent and 2 because of 
incomplete data. Death was recorded, but the patient who died was excluded from the 
study and it was not reported whether they received O2. No other selective reporting was 
identified.  
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Ukholkina  20,21 2005 
There is no description of how randomisation sequence was generated or whether 
allocation was concealed. Baseline characteristics differ in the two groups for: time to 
revascularisation (41 minutes shorter in the air group (P=0.052)) and Killip classification: 
(Killip class II was present in 10% O2 vs. 1% air group (P=0.08) (class III and IV were 
excluded from the study)).  Both are potential confounders which could have led to 
overestimation of comparative mortality in the O2 group. 
Blinding was not undertaken. The primary outcome, death, and other outcomes such as 
recurrent MI and pericarditis are hard outcomes and unlikely to be subjected to significant 
observer bias.  It may have led to performance bias.  The study has possible bias in 
infarct size estimation: CPK-MB was not measured at the same time from onset in all 
patients and PCI can alter biomarker release; no information is provided about number or 
blinding of observers, reliability and repeatability of measurements for ECG mapping. 
Furthermore, ECG-mapping for assessing infarct size was used only in a subset of 
patients. 
No patients were lost to follow up. There is no explicit data on patients excluded post-
randomisation due to failed revascularisation, or the number of failed revascularisations 
per group. The mismatch between numbers reported in the tables and the text suggest 
two patients may have been excluded from the air group and four from the O2 group. Data 
in Table 3 of the study report did not make sense for “No complications” for the air group. 
We recalculated complication rates for this group for the outcome tables in our analysis.  
Results of individual studies 
Rawles 18  1976 
8.6% of randomised patients (11.2% with confirmed AMI) in the O2 group died (one in the 
first 24 hours while still on therapy) and 3.2% of randomised patients (3.9% of those with 
confirmed MI) in the air group died (two of them in the first 24 hours). RR of death was 
2.89 (95%CI 0.81 to 10.27) in confirmed AMI and  2.71 (95%CI 0.76 to 9.73) in ITT 
population. 
Diamorphine use was reported as a proxy for pain. It was administered in 54.3% of the O2 
group (71.3% of those with confirmed AMI). The average was 2.1 doses (SD 1.5), but it is 
unclear whether the denominator was those using diamorphine or all patients.  In the air 
group, 54.7% received diamorphine (67.5% of those with confirmed AMI). The average 
was 2.0 doses (SD 1.4), but the denominator was unclear.  The RR for the use of 
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analgesia was 1.06 (95%CI 0.86 to 1.30) in confirmed AMI and 0.99 (95%CI 0.77 to 1.28) 
in the ITT population.  
Wilson 19  1997  
There was one death, but we were unable to determine in which group this occurred.  
Both authors confirmed they no longer had the trial data and did not remember in which 
arm the death and the stroke occurred.  25 were randomised into each group.  
Opiate use was recorded as a proxy for pain. Although 50 patients were randomised, 
results were only reported for 42.  Sixteen out of 22 patients (72.7%) in the O2 group used 
opiates and 18 out of 20 patients (90%) in the air group used opiates. The RR of need for 
analgesia was 0.81 (95%CI 0.60 to 1.08) in the reported groups and 0.89 (95%CI 0.61 to 
1.30) on an ITT basis. There was no difference in ECG ST-segment changes between the 
groups 
Ukholkina  20,21 2005  
One patient out of 58 died in the O2 group and none out of 79 in the air group. RR of death 
was 4.07 (95%CI 0.17 to 98.10).  
Complications of AMI (excluding angina), were reported in 8 out of 58 (13.8%) in the 
oxygen group and 24 out of 79 (30.4%) in the air group. RR of complications was 0.45 
(95%CI 0.22 to 0.94). 
The authors used several techniques to estimate the infarct size. Although they conclude 
that oxygen “reduced the area of necrosis and peri-infarction area, improved central 
hemodynamic, and decreased the rate of postoperative rhythm disorders as compared to 
patients breathing ambient air”, we felt that this could not be concluded confidently 
because of the methodological weaknesses discussed above. 
Synthesis of results  
There were only sufficient data to perform meta-analyses for death and opiate use from 
two of the three trials (Rawles18 and Ukholkina 20,21 for death, and Rawles18 and Wilson19 
for pain). There was no heterogeneity in the ITT analyses.  
The meta-analysis showed a RR of death for patients in the O2 group of 3.03 (95%CI 0.93 
to 9.83) in confirmed AMI and 2.88 (95%CI 0.88 to 9.38) in the ITT population (Figure 3). 
The meta-analysis for analgesic use gives a RR of 0.99 (95%CI 0.83 to 1.18) in confirmed 
AMI and 0.97 (95%CI 0.78 to 1.20) (Figure 4) in the ITT population. 
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Risk of bias across studies 
The risk of bias across studies is high.  Risk of bias is “Unclear” for adequate sequence 
generation and allocation concealment and “High” for blinding, completeness of outcome 
data, selective outcome reporting and other biases. 
Additional analysis 
We did a sensitivity analysis for missing information on the arm in which the death 
occurred in the Wilson trial.19 The worst-case scenario assumes that the patient who died 
was in the O2 arm and gives a RR of death of 2.88 (95%CI 0.88 to 9.38) using ITT 
analysis. The best-case scenario assumes that the patient who died received air, giving a 
RR of death of 2.06 (95%CI 0.67 to 6.37) using ITT analysis. 
Discussion    
Only three trials, involving a total of 387 patients, were found.  None demonstrated that O2 
therapy in AMI does more good than harm.  In both the ITT and the confirmed AMI meta-
analyses, there were more deaths amongst those on O2 than those on air, although this 
did not reach statistical significance and could simply be a chance occurrence.  There was 
no clinically or statistically significant difference in analgesia use. In the meta-analysis for 
analgesic use in confirmed AMI we found moderate heterogeneity (I2 = 54%) but it 
disappeared in the ITT analysis. While the two studies used in the meta-analysis had 
differences in design (blind vs. open label) and attrition rates (higher in the Wilson 19 
study), it is not possible to investigate heterogeneity further with only two trials.  
This review has a number of limitations. Firstly, the evidence in support of such a 
widespread practice is surprisingly sparse and scattered. We were unable to analyse if 
there was any publication bias using formal methods as only three studies were found.  
The possibility that there are unpublished studies and or other published studies, 
especially in foreign languages, that are not indexed in the electronic databases cannot be 
excluded.   
Secondly, the quality of included studies was generally poor and risk of bias was high for 
both outcomes.  Two studies (Rawles18 and Wilson19) were old and prior to improvements 
in trial design, conduct and reporting that have taken place in the last decade. Therefore 
results must be interpreted with caution.  
Thirdly, the Rawles18 study was undertaken in the pre-reperfusion era and thus may not 
be applicable today. Moreover, case fatality rates from AMI have fallen over the last 30 
 14 
years due to improved management including reperfusion and the use of medical 
treatments such as beta-blockers, aspirin or angiotensin-converting enzyme inhibitors.22 
Finally, overall death rate among controls during hospital stay in the included studies was 
only 1.7%. This is lower than observed in contemporaneous routinely collected data.22   
While this may be explained by the fact that low risk patients were recruited, it could also 
be due to a chance deficit of mortality in the control arm (which could have contributed to 
the apparent excess of deaths in the O2 arm).  
Conclusion 
The evidence in this area is sparse, of poor quality and pre-dates advances in reperfusion 
techniques and trial methods. What evidence there is, is suggestive of harm but lacks 
power and excess deaths in the O2 group could be due to chance.  Current evidence 
neither supports nor refutes the routine use of O2 in patients with uncomplicated AMI. 
Implications for research 
As long ago as 1950, it was demonstrated that the administration of pure O2 via face mask 
not only failed to reduce duration of angina pain, but also prolonged  ECG changes 
indicative of acute myocardial ischaemia.23 This topic was  identified as requiring further 
research over three decades ago.24  It is surprising that a definitive study has not been 
undertaken.   
We searched ClinicalTrials.gov and the World Health Organisation International Clinical 
Trials Registry Platform for ongoing trials of oxygen in AMI and identified two studies, 
from Australia and New Zealand, neither of which (one hospital based, the other pre-
hospital, recruiting around 200 patients each) is powered for mortality. We have 
calculated that around 10 thousand patients would need to be randomised to receive 
oxygen, and another 10 thousand to air, to address the question of whether oxygen 
improves or increases mortality. We are working with colleagues from ambulance 
services, cardiology, emergency medicine and public health to plan such a trial. Given 
the widespread use of oxygen in AMI, the inconsistency in guideline recommendations 
about when and to whom it should be given, and the fact that the best current evidence 
is suggestive of potential clinically significant harm, the need to clarify this uncertainty 
is urgent.  
A strong a priori belief,14, 15, 25 based on pathophysiological reasoning, that O2 
administration is beneficial, may have precluded funding of a definitive trial to date.  
Potential mechanisms causing harm 
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It is biologically plausible that O2 is doing harm.  Potentially harmful mechanisms include 
the paradoxical effect of reducing coronary blood flow and increasing coronary vascular 
resistance26;27; reduced stroke volume and cardiac output 28; other adverse 
haemodynamic consequences, such as increased vascular resistance from hyperoxia; 
and reperfusion injury from increased oxygen free radicals.29,30   
Potential mechanisms by which O2 might harm cardiac patients have been explored in 
two recent reviews. In their systematic review, Farquhar et al  30 concluded that 
hyperoxia caused significant reduction in coronary blood flow due to a mean increase 
in coronary vascular resistance, suggesting that hyperoxia is a potent vasoconstrictor 
stimulus to the coronary circulation, functioning at level of microvascular resistance 
vessels. They also found that hyperoxia led to a reduction in myocardial O2 
consumption, due both to reduction in O2 delivery and myocardial O2 demand, shown to 
be associated with reduced myocardial contractility (although they identify conflicting 
study results).  Moradkhan and Sinoway, 31 in a narrative review, suggest that, with 
widespread use of high concentration O2 in cardiac patients to maintain oxygen 
saturations close to 100%, many patients are consequently exposed to significant 
periods of hyperoxia, resulting in coronary vasoconstriction as a result of generation of 
reactive oxygen species, a fall in intracellular ATP concentrations mediating opening of 
ATP-sensitive potassium channels, in turn causing hyperpolarisation of vascular 
smooth muscle cells and vasodilation. Hyperoxia may also induce vasoconstriction 
through acting directly on L-type calcium channels, and may affect release of 
angiotensin II, with subsequent changes in endothelin-1 levels, increasing vascular 
tone. Hyperoxia is also thought to increase production of the potent vasoconstrictor 20-
HETE. Moreover, in critically ill patients, high flow O2 causes misdistribution of 
microcirculatory blood flow, with increased O2  shunting and reduction in O2 
consumption.
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A new consensus? 
Emerging guidelines are beginning to diverge from the previous consensus that O2 
should routinely be administered in AMI, but this ‘new consensus’ is largely based on 
expert opinion rather than robust evidence of what we should do. 8,9, 32-35 A recent BMJ 
editorial argued that O2 continue to be routinely used based on pathophysiological 
reasoning, as none of the studies in the Farquhar 30 review included patients with AMI 
36
. Clearly there is ongoing uncertainty about the role of O2 in AMI. 
Decades after the Rawles trial,18 we still do not know whether routine O2 administration 
is beneficial, harmful, or irrelevant in AMI.  Nor do we have robust evidence that O2 is 
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beneficial in ‘complicated’ patients such as those with shock or arrhythmia, and 
concern has been raised about hyperoxia in patients resuscitated from cardiac arrest.37   
We need to generate good evidence, from adequately powered randomised controlled 
trials (RCTs) to guide decisions on which patients - if any - should receive O2, at what 
dose, and for how long.   
Given widespread use, the inconsistency in recommendations about when and to whom it 
should be given, and the fact that the best current evidence is suggestive –but not 
conclusive proof -  of potential harm from O2, the need to clarify this uncertainty is urgent.  
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